Abstract: A distributed system of scanning nodes is provided job portions to collectively scan network systems numbering in the tens of thousands and beyond million across the Internet. A scanning controller creates the job portions to fulfill a scanning request. The scanning controller creates the job portions based on availability of scanning nodes and a size of the scanning request (i.e., number of network addresses indicated by the request). The scanning controller creates each job portion with scanning instructions for an available scanning node to execute on a selected set of the network addresses indicated in the request, with each job portion having a different set of addresses to scan and being independently executable.

Abstract: A system for scanning a network includes an interface and a processor. The interface is configured to receive an indication to scan a set of network addresses. The processor is configured to determine a set of available scanning nodes and determine a job plan for scanning the set of network addresses using the set of available scanning nodes. The job plan includes one or more job portions. The processor is configured to, for a job portion of the one or more job portions, select a scanning node of the set of available scanning nodes and provide the job portion to the scanning node.

Abstract: A system for scanning a network includes an interface and a processor. The interface is configured to receive an indication to scan a set of network addresses. The processor is configured to determine a set of available scanning nodes and determine a job plan for scanning the set of network addresses using the set of available scanning nodes. The job plan includes one or more job portions. The processor is configured to, for a job portion of the one or more job portions, select a scanning node of the set of available scanning nodes and provide the job portion to the scanning node.

Abstract: A cladding system, intended to exclude water from within a building having a cavity wall structure, includes passive means (a) for minimising any flow of water from the exterior that may reach the interior, and (b) open guides or enclosed channels for diverting such water so that it flows by gravity down the cavity to be drained outwardly. One implementation provides impervious battens modified to have water-diverting sides, and another provides solid slabs including channels connected by drainage cuts along their length to a surface to be drained.

Abstract: Heterocyclic compounds of the formula (I) are provided: wherein ring A, ring B, R1, R2, R3, R4, Y, m, n and q are as identified herein. R1 is in particular amidino. The invention further provides particular benzothiophene compounds. Compounds of the invention may be useful as inhibitors of Factor IXa and in the therapy of cardiovascular conditions and diseases, e.g. thrombosis.

Abstract: A method for treating a substrate having a layer or coating of material thereon (such as for example a metal conductor coated with an insulating ‘enamel’) comprises the steps of directing a pulsed beam of laser radiation at the substrate to cause an interaction or adjacent the interface between the layer or coating and the substrate, leading to local separation of the layer or coating. The removal is effected by creating an interaction effect at the interface between the substrate and the layer or coating to create an effect similar to a shockwave which causes local separation of the layer or coating at the interface.

Abstract: The invention comprises a cladding member formed by a member of insulating material having front and rear faces and top, bottom faces and side faces. The front face has a plurality of substantially parallel channels formed there. The cladding members can be associated with base blocks. The base blocks have a moisture receiving means to receive moisture from the channels of the cladding members, and discharge means to allow such moisture to be discharged from the receiving means. Flashings and fixing devices are also described.

Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or solvate of either entity, wherein R4 is a guanidinyl moiety and the other substituents are as defined in the text, are urokinase inhibitors.

Abstract: A server computer updates client computers' copies of subscription files stored on a network. The server computer retrieves a database record from a subscription database. The database record includes at least client computer and subscription file information. The server computer checks the subscription file stored on the network for any changes which may have occurred to the file since the previous checking of the subscription file preferably by comparing the last save time stamp to a time stamp on the subscription file stored on the network. If changes have occurred, the server computer creates an update file for the client computer and transmits the update file to the client computer, preferably by electronic mail. Each database record may further contain a check interval indicating the periodicity of the checking of the subscription file for changes. The database record may further contain a time last checked field which is updated each time the subscription file is checked for changes.

Abstract: Compounds of formula (I):- 1

Abstract: A server computer generates an update file for transmission to a client computer that permits the client computer to generate a copy of a current version of a subscription file from a copy of an earlier version of the subscription file. For each segment of the current version of the subscription file, the server computer searches an earlier version of a signature list for an old segment signature which matches a new segment signature corresponding to the segment. When a match is detected, the server computer writes a command in the update file for the client computer to copy an old segment of the client computer's copy of the earlier version of the subscription file into the client computer's copy of the current version of the subscription file, where the old segment corresponds to the segment for which a match was detected.

Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or solvate of either entity, wherein R4 is a guanidinyl moiety and the other substituents are as defined in the text, are urokinase inhibitors.

Abstract: A server computer generates an update file for transmission to a client computer that permits the client computer to generate a copy of a current version of a subscription file from a copy of an earlier version of the subscription file. For each segment of the current version of the subscription file, the server computer searches an earlier version of a signature list for an old segment signature which matches a new segment signature corresponding to the segment. When a match is detected, the server computer writes a command in the update file for the client computer to copy an old segment of the client computer's copy of the earlier version of the subscription file into the client computer's copy of the current version of the subscription file, where the old segment corresponds to the segment for which a match was detected.

Abstract: Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R1 and R2 are optional substituents and independently represent C1-6 alkyl, C2-6 alkenyl, optionally substituted by CO2H or CO2(C1-6 alkyl), C2-6 alkynyl, halogen, C1-3 perfluoroalkyl, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 or CONH(CH2)mHet1; R3 represents H, C1-6 alkyl, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCO2R10, C2-6 alkenyl, C2-6 alkynyl, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 or (CH2)pOR10; R4 represents H or C1-6 alkyl; R5 represents H or OH; R6 represents phenyl optionally fused to a heterocyclic ring, the group as a whole being optionally substituted; R7-10 are fully defined herein and may independently represent Ar2 or Het2; Z represents CO2H, CONH(tetrazol-5-yl), CONHSO2O(C1-4 alkyl), CO2Ar3, CO2(C1-6 alkyl), tetrazol-5-yl, CONHSO2Ar3, CONHSO2(CH2)qAr3 or

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors

Abstract: A photopolymerizable composition for making screen printing stencils. The composition comprises polyvinyl alcohol having at least one photocrosslinkable group appended thereto. At least one metal salt, wherein the metal is selected from: aluminum, zinc, chromium, zirconium, titanium, tin or iron, is added to the composition. The metal salt is used to improve water resistance of a screen printing image that is prepared from the photopolymerizable composition.

Abstract: Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R1 and R2 are optional substituents and independently represent C1-6 alkyl, C2-6 alkenyl, optionally substituted by CO2H or CO2(C1-6 alkyl), C2-6 alkynyl, halogen, C1-3 perfluoroalkyl, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 or CONH(CH2)mHet1; R3 represents H, C1-6 alkyl, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCO2R10, C2-6 alkenyl, C2-6 alkynyl, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 or (CH2)pOR10; R4 represents H or C1-6 alkyl; R5 represents H or OH; R6 represents phenyl optionally fused to a herterocyclic ring, the group as a whole being optionally substituted; R7-10 are fully defined herein and may independently represent Ar2 or Het2; Z represents CO2H, CONH(tetrazol-5-yl), CONHSO2O(C1-4 alkyl), CO2Ar3, CO2(C1-6 alkyl), tetrazol-5-yl, CONHSO2Ar3, CONHSO2(CH2)qAr3 o

Abstract: 1

Abstract: Compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N═C(NH2)2 or NHC(═NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.

Abstract: The invention provides S-(+)-3-{1-(1,3-benzodioxol-5-yl)-2-[(2-methoxy-4-methylphenyl)sulfonylamino]-2-oxoethyl}-1-methyl-1H-indole-6-carboxylic acid, which is substantially free from its (R)-(−)-enantiomer, and pharmaceutically acceptable derivatives thereof. The compounds are useful in the treatment of inter alia acute renal failure, restenosis and pulmonary hypertension.